



## Structured Administration and Supply Agreement

### SASA Details

|                     |  |
|---------------------|--|
| Title:              | Lignocaine 1 % for perineal infiltration |
| Identifying Number: | <a href="#">ED-CO-24-239365</a>          |

### Issuing Authority

|                |   |
|----------------|---|
| Hospital Name: | WACHS CEO under section 6 Medicine and Poisons Regulations 2016 |
| Address:       | 189 Wellington Street, PERTH 6000                               |
| Contact:       | 9223 8525   |

### Authorised Persons

|                |   |
|----------------|---|
| Practitioners: | Midwives  |
| Location:      | WACHS Maternity units, Midwifery Group Practice and home birth programs |
| Qualification: | APHRA registered Midwives   |

### Authorised Medicine

|                |  |           |  |
|----------------|--|-----------|--|
| Medicine Name: | Lidocaine (Lignocaine) 1 %   | Brand:    |  |
| Form:          | Injection  | Strength: | 50 mg /5 ml<br>200mg/ 20ml                                     |
| Dose:          | 10 mls perineal infiltration prior to episiotomy<br>10 - 20 mls perineal infiltration prior to perineal repair         | Quantity: | The total dose shall not exceed 200 mg (20 ml) within one hour |
| Route:         | Subcutaneous infiltration  |           |  |
| Instructions:  | Withdraw the plunger of the syringe back prior to injecting slowly to prevent accidental injection into a blood vessel |           |  |

### Approved Circumstances

|                |   |
|----------------|---|
| Authorised to: | Perineal care and repair by midwives deemed WACHS competent to do so    |
| Place:         | WACHS Maternity units, Midwifery Group Practice and home birth programs |
| Patients:      | Consenting women intrapartum and post-birth                             |

Lidocaine for perineal infiltration

|                    |  |
|--------------------|--|
| Medical Condition: | Requiring episiotomy and /or perineal repair |
|--------------------|--|

| Clinical / Other Information |   |
|------------------------------|---|
| Patient Inclusion            | Women who consent to episiotomy and /or perineal repair post birth  |
| Patient Exclusion:           | Contraindications: <ul style="list-style-type: none"> <li>• Known allergy to lignocaine</li> <li>• Consent not obtained</li> <li>• Infection at the site of injection</li> </ul>                              |
| Special Instructions:        | Adult Resuscitation equipment must be available.  |
| Administration Notes:        | As per relevant KEMH clinical guidelines  |
| Clinical Guidelines          | <a href="#">KEMH Intrapartum Care – second stage of labour – Episiotomy and infiltration of the perineum</a><br><a href="#">KEMH Clinical Practice Guideline – Episiotomy / Genital Laceration : suturing</a> |

| Approval                      |   |            |                  |
|-------------------------------|---|------------|------------------|
| Date of Issue:                | 31/07/2024                              |            |                  |
| Date of Expiry:               | 30/07/2026                              |            |                  |
| Clinical Governance Committee |   |            |                  |
| Committee:                    | Medicines and Therapeutics Committee    |            |                  |
| Chair:                        | Dr Helen Van Gessel                     |            |                  |
| Date:                         | 26 June 2024                            | Signature: | Helen Van Gessel |
| Nurse                         | Kate Reynolds, Coordinator of Midwifery |            |                  |
| Date                          | 01 July 2024                            | Signature: | Kate Reynolds    |
| Senior Medical Practitioner   |   |            |                  |
| Name:                         | Dr Helen van Gessel                     |            |                  |
| Date:                         | 26 June 2024                            | Signature: | Helen Van Gessel |
| Chief Executive               |   |            |                  |
| Name:                         | Mr Jeff Moffet                          |            |                  |
| Date:                         | 31 July 2024                            | Signature: | Jeff Moffet      |

Lidocaine for perineal infiltration